文献速递头颈外科

口咽癌新辅助化疗联合经口机器人手术后的生活质量

Quality of Life After Neoadjuvant Chemotherapy and Transoral Robotic Surgery for Oropharynx Cancer.
PubMed 文献 · JAMA Otolaryngol Head Neck Surg · 2024-01-01

这项多中心前瞻性队列研究纳入67例接受新辅助化疗后经口机器人手术及颈清扫(NECTORS)方案的人乳头瘤病毒相关口咽鳞状细胞癌(HPV-OPSCC)患者,评估患者报告的生活质量与功能结局。24个月时总体生活质量较基线改善(均差9.49;95%CI 2.45至16.53),EORTC QLQ-C30功能评分在治疗后3至6个月内恢复至基线或改善并在24个月保持稳定。

要点

  • 24个月总体生活质量较基线改善,均差9.49(95%CI 2.45至16.53)。
  • EORTC QLQ-C30功能评分在治疗后3至6个月内恢复至基线或改善,24个月保持稳定。
  • 吞咽相关生活质量基线至12个月无显著差异。

核心结论

  • 多中心队列研究提示NECTORS方案与优良的生活质量结局相关,生活质量指标恢复至基线或优于基线。

研究设计与样本

  • 2017至2022年多中心前瞻性队列研究,纳入接受NECTORS方案治疗的III期或IVa期HPV-OPSCC连续患者。
  • 94例符合条件,67例纳入分析,均在基线和24个月随访期内至少完成一次主要生活质量问卷。

主要发现

  • 67例患者中位(范围)年龄63(58-67)岁,男性54例(80.6%);最常见肿瘤部位为腭扁桃体41例(61%)和舌根26例(39%);均未需要辅助放疗。
  • 24个月总体生活质量较基线改善,均差9.49(95%CI 2.45至16.53)。
  • EORTC QLQ-C30功能评分在治疗后3至6个月内恢复至基线或改善,24个月保持稳定;EORTC QLQ-HN35症状量表评分在24个月改善或稳定。
  • 吞咽障碍问卷(MD Anderson Dysphagia Inventory)基线至12个月总体评分均差6.15(95%CI -4.18至16.49)、综合评分均差2.73(95%CI -1.62至7.09),均无显著差异。
  • 决策后悔量表评分中位(范围)为100分中5分(0-30),代表轻度总体后悔。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Efforts are underway to deintensified treatment protocols for patients with human papillomavirus virus-associated oropharyngeal squamous cell carcinoma (HPV-OPSCC) to achieve similar excellent oncologic outcomes while reducing treatment-related adverse effects. Transoral robotic surgery (TORS) as primary treatment often requires adjuvant therapy due to the high incidence of nodal metastasis. Treatment with neoadjuvant chemotherapy followed by TORS and neck dissection (NECTORS), reserving radiation therapy for salvage, yields excellent oncologic outcomes. OBJECTIVE: To assess patient-reported quality of life (QOL) and functional outcomes among patients with HPV-OPSCC who undergo NECTORS. DESIGN, SETTINGS, AND PARTICIPANTS: This was a multicenter prospective cohort study of patients with HPV-OPSCC treated with the NECTORS protocol in 2017 to 2022. Consecutive patients with stage III or IVa HPV-OPSCC treated with NECTORS in 2017 to 2022 who had completed the primary QOL questionnaire at baseline and at least once during the 24-month follow-up period were included. Ninety-four patients were eligible, and 67 were included in the analyses. OUTCOME MEASURES: QOL questionnaires at baseline, and at month 1, 3, 6, 12, 18, and 24 posttreatment. Global score on the 30-item European Organization for Research and Treatment of Cancer Core quality of life questionnaire (EORTC QLQ-C30) was the primary outcome; the head and neck extension module (EORTC QLQ-HN35); the MD Anderson Dysphagia Inventory for dysphagia-related QOL; and the Decision Regret Scale were also used. Paired t tests assessed change between the baseline and 12- or 24-month patient-reported outcomes. RESULTS: Among the study population of 67 patients (median [range] age, 63 [58-67] years; 54 [80.6%] male) with HPV-OPSCC, the most frequent cancer subsites were palatine tonsil (41 [61%]) and base of tongue (26 [39%]); none required adjuvant RT. Global QOL at 24 months improved compared with baseline (mean difference, 9.49; 95% CI, 2.45 to 16.53). All EORTC QLQ-C30 functional scores returned to baseline or improved within 3 to 6 months posttreatment and remained stable at 24 months. EORTC QLQ-HN35 symptom scale scores improved or were stable at 24 months. The MD Anderson Dysphagia Inventory scores demonstrated no significant difference between baseline and month 12 for global scores (mean difference, 6.15; 95% CI, -4.18 to 16.49) and composite scores (mean difference, 2.73; 95% CI, -1.62 to 7.09). Median (range) score on the Decision Regret Scale was 5 of 100 (0-30), representing mild overall regret. CONCLUSION AND RELEVANCE: The findings of this multicenter cohort study indicate that use of the NECTORS protocol is associated with excellent QOL outcomes. QOL measures returned to baseline levels or were better than baseline, which represents positive outcomes for patients with HPV-OPSCC who undergo this treatment regimen.

来源:JAMA Otolaryngol Head Neck Surg,查看原文。版权归原作者所有。

引用

  1. Silver JA, Bouganim N, Richardson K, et al. Quality of Life After Neoadjuvant Chemotherapy and Transoral Robotic Surgery for Oropharynx Cancer. JAMA Otolaryngol Head Neck Surg. 2024. PMID: 38060238. doi:10.1001/jamaoto.2023.3781

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。